TOKYO, May 18 (Pulse News Wire) – Kringle Pharma,inc. (4884.T) hosted an online briefing on May 18, 2026 to address key questions related to its ongoing spinal cord injury clinical trials.
During the session, the company confirmed plans to initiate additional Phase III trials within the current fiscal year, contingent upon regulatory approval. Detailed trial protocols will be disclosed once the application is accepted by the Pharmaceuticals and Medical Devices Agency (PMDA). In addition, Kringle Pharma outlined its strategic focus on expanding research activities in the United States, emphasizing the importance of building relationships with key opinion leaders and securing funding through partnerships and government grants.
The company also reported positive feedback from recent presentations at international medical conferences, highlighting significant interest in their treatment approaches for severe spinal injuries. Regarding future development strategies, Kringle Pharma stated it would prioritize acute phase treatments while exploring chronic phase opportunities through collaborative research efforts. The firm expects to share updates on European expansion plans as domestic and US developments progress.
🟡 Confidence: Standard AI-translated content.